The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Capricor Therapeutics shares plummeted 67.7% following market warning signs and a negative vote from a U.S. FDA expert panel. The panel rejected effectiveness data for the company's cell therapy targeting Duchenne muscular dystrophy-related heart conditions. Consequently, law firms initiated investigations into potential federal securities law violations following reports of a failed Phase 3 trial. These developments led to a further 60% drop in premarket trading on July 30.